https://www.avient.com/sites/default/files/AVNT Q1 2023 Earnings Press Release.pdf
A recording of the webcast and the slide presentation will be available at
avient.com/investors/events-presentations immediately following the conference call and will be
accessible for one year.
Three Months Ended
March 31, 2023
Three Months Ended
March 31, 2022
Reconciliation to Condensed Consolidated Statements of Income $ EPS $ EPS
Net income from continuing operations attributable to Avient shareholders $ 20.8 $ 0.23 $ 64.4 $ 0.70
Special items, after tax (Attachment 3) 22.3 0.24 6.4 0.07
Amortization expense, after-tax 15.1 0.16 10.8 0.12
Adjusted net income / EPS $ 58.2 $ 0.63 $ 81.6 $ 0.89
8
Attachment 2
Avient Corporation
Condensed Consolidated Statements of Income (Unaudited)
(In millions, except per share data)
Three Months Ended
March 31,
2023 2022
Sales $ 845.7 $ 892.2
Cost of sales 598.1 637.8
Gross margin 247.6 254.4
Selling and administrative expense 190.5 152.2
Operating income 57.1 102.2
Interest expense, net (28.8) (16.9)
Other income (expense), net 0.7 (0.6)
Income from continuing operations before income taxes 29.0 84.7
Income tax expense (7.7) (20.0)
Net income from continuing operations 21.3 64.7
(Loss) income from discontinued operations, net of income taxes (0.9) 19.8
Net income 20.4 84.5
Net income attributable to noncontrolling interests (0.5) (0.3)
Net income attributable to Avient common shareholders $ 19.9 $ 84.2
Earnings (loss) per share attributable to Avient common shareholders - Basic:
Continuing operations $ 0.23 $ 0.70
Discontinued operations (0.01) 0.22
Total $ 0.22 $ 0.92
Earnings (loss) per share attributable to Avient common shareholders - Diluted:
Continuing operations $ 0.23 $ 0.70
Discontinued operations (0.01) 0.21
Total $ 0.22 $ 0.91
Cash dividends declared per share of common stock $ 0.2475 $ 0.2375
Weighted-average shares used to compute earnings per common share:
Basic 91.0 91.5
Diluted 91.8 92.3
9
Attachment 3
Avient Corporation
Summary of Special Items (Unaudited)
(In millions, except per share data)
Special items (1) Three Months Ended
March 31,
2023 2022
Cost of sales:
Restructuring costs, including accelerated depreciation $ (6.6) $ (4.4)
Environmental remediation costs (1.4) (2.0)
Reimbursement of previously incurred environmental costs — 0.6
Impact on cost of sales (8.0) (5.8)
Selling and administrative expense:
Restructuring, legal and other (15.7) 1.9
Acquisition related costs (3.4) (2.9)
Impact on selling and administrative expense (19.1) (1.0)
Impact on operating income (27.1) (6.8)
Other income (loss), net (0.2) 0.1
Impact on income from continuing operations before income taxes (27.3) (6.7)
Income tax expense (benefit) on above special items 6.9 1.8
Tax adjustments(2) (1.9) (1.5)
Impact of special items on net income from continuing operations $ (22.3) $ (6.4)
Diluted earnings per common share impact $ (0.24) $ (0.07)
Weighted average shares used to compute adjusted earnings per share:
Diluted 91.8 92.3
(1) Special items include charges related to specific strategic initiatives or financial restructuring such as: consolidation of operations; debt
extinguishment costs; costs incurred directly in relation to acquisitions or divestitures; employee separation costs resulting from personnel
reduction programs, plant realignment costs, executive separation agreements; asset impairments; settlement gains or losses and mark-to-
market adjustments associated with actuarial gains and losses on pension and other post-retirement benefit plans; environmental remediation
costs, fines, penalties and related insurance recoveries related to facilities no longer owned or closed in prior years; gains and losses on the
divestiture of operating businesses, gains and losses on facility or property sales or disposals; results of litigation, fines or penalties, where
such litigation (or action relating to the fines or penalties) arose prior to the commencement of the performance period; one-time, non-recurring
items; and the effect of changes in accounting principles or other such laws or provisions affecting reported results
https://www.avient.com/sites/default/files/2021-09/avnt-seaport-conference-presentation.pdf
It’s in this spirit that we joined legacy PolyOne and the Clariant Masterbatch business,
two complementary businesses, and formed a new one that we’ve named Avient.
As one, we are better positioned than ever before to lead and to make a positive
difference.
D
is
t.
)
LB
Median: 5%Median: 3%
Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M)
Avient Specialty
Other
Free Cash Flow Conversion (1)
2021E (%)
Being asset light helps us to generate
strong free cash flow that is in line
with specialty formulators.
https://www.avient.com/sites/default/files/2021-03/avient-antitrust-2021-update-turk-a4.pdf
Kendinizi rakiple bir anlaşma yapıldığı izlenimini
yaratabilecek veya akla getirebilecek durumlara
sokmayın Bir iş bülteni veya bir gazetenin ön
sayfasında gördüğünüzde kendinizi rahatsız
hissedebileceğiniz hiçbir şey yapmayın.
Müşterinizin bağımsızlığına saygı duyun;
Avient Hukuk Departmanının ön onayı olmaksızın
müşterinizin Avient ürünlerini satma gücü üzerinde
fiyat, bölge, müşteri veya son kullanım kısıtlamaları
tesis etmeyin.
10.
Bundan başka, Avient Hukuk
Departmanından ön onay almaksızın, bir müşteriye
başka bir ürün veya hizmeti satma koşuluyla bir
ürün veya hizmeti satın alma koşulunu müşteriye
getirmeyin.
13.
https://www.avient.com/sites/default/files/2024-03/Luxury Closures Application Bulletin_Online.pdf
Add weight while simplifying your processing
steps – Simplify your manufacturing process by
injection molding a weighted, finished part in one
step rather than adding a metal weight.
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Colorants and Formulations_Functional Additives for IVD Devices Bulletin.pdf
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified
manufacturing sites, providing global
consistency and increased security of supply
• Documented change control beyond CAS
number, reducing risk of change
• Non-phthalate and formulated without
animal-derived substances
• Available as concentrates or ready-to-use
formulations in a wide range of polymers
• Functionality and color can be combined in
one product for convenience
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III) and/or
Device Master File
• Documentation support for approval or
transition to comply with (new) regulations
such as IVDR
APPLICATION BULLETIN
Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2020-12/resound-om-technical-bulletin_0.pdf
Available in four overmolding grades compatible
with polypropylene (PP), and one grade that is
suited for overmolding onto ABS, all grades are
formulated for durability, delivering property
retention and UV resistance comparable to
traditional TPEs.
https://www.avient.com/sites/default/files/2022-11/Wilflex Epic Rio Ready-for-Use Standard Colors Interactive Color Card.pdf
SIMPLE
Save time on mixing with ready-for-use colors that
are accurate and repeatable from one job to the
next.
https://www.avient.com/sites/default/files/2021-01/amendment-to-articles-commercial-registration-avient-corporation.pdf
Check one box below and provide information as required:
Complete the following information:
Form 540 Prescribed by:
POLYONE CORPORATION
1181191
1701.70(B)(6)
Page 2 of 2Form 540 Last Revised: 06/2019
A copy of the resolution of amendment is attached to this document.
https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-custom-pa-grade-heat-shield-component.pdf
https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-therma-tech-led-light-heat-exchanger.pdf